Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lipegfilgrastim→

Lipegfilgrastim Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1117844-87-7
Molecular formula
Not available
Molecular weight
Not available
Drug class
Long-acting granulocyte colony-stimulating factor (G-CSF)immunostimulant
Mechanism of action
A glycoPEGylated G-CSF analogue that binds G-CSF receptors on haematopoietic cells, stimulating neutrophil precursor proliferation and differentiation and supporting neutrophil recovery.
Indications / reported uses
  • Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients receiving cytotoxic chemotherapy for malignancy, under the authorised product indication.

Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Lipegfilgrastim Environmental Risk Assessment (ERA) (the Lipegfilgrastim ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.